AmMax

AmMax, launched in March 2020 through a collaboration between LifeMax and Amgen, is a privately held clinical-stage biotechnology company dedicated to unlocking the therapeutic potential of the CSF1R platform ("Colony Stimulating Factor 1 Receptor") to address diseases with significant unmet medical needs and considerable market potential. We have two clinical-stage programs preparing to enter Phase 2 studies. The CSF1/CSF1R axis is physiologically crucial but can drive pathological changes in various biological processes affecting multiple organs such as the lungs, liver, and kidneys. Leveraging its mechanistic insights into CSF1/CSF1R biology, AmMax is building and expanding an anti-inflammatory, anti-fibrotic, and anti-neovascular technology platform targeting CSF1R, which holds broad therapeutic potential across various critical disease states. AmMax's robust pipeline based on the CSF1R platform captures best-in-class opportunities that are clinically or preclinically validated/supported, well-differentiated, and capable of delivering significant clinical benefits to patients. With an experienced management team, versatile technology platform, and strong pipeline, AmMax is poised to grow into a leading biotechnology company.